New 1,3,4-Thiadiazole Derivatives with Anticancer Activity

Molecules. 2022 Mar 10;27(6):1814. doi: 10.3390/molecules27061814.

Abstract

We designed and synthesized the 1,3,4-thiadiazole derivatives differing in the structure of the substituents in C2 and C5 positions. The cytotoxic activity of the obtained compounds was then determined in biological studies using MCF-7 and MDA-MB-231 breast cancer cells and normal cell line (fibroblasts). The results showed that in both breast cancer cell lines, the strongest anti-proliferative activity was exerted by 2-(2-trifluorometylophenylamino)-5-(3-methoxyphenyl)-1,3,4-thiadiazole. The IC50 values of this compound against MCF-7 and MDA-MB-231 breast cancer cells were 49.6 µM and 53.4 µM, respectively. Importantly, all new compounds had weaker cytotoxic activity on normal cell line than on breast cancer cell lines. In silico studies demonstrated a possible multitarget mode of action for the synthesized compounds. The most likely mechanism of action for the new compounds is connected with the activities of Caspase 3 and Caspase 8 and activation of BAX proteins.

Keywords: 1,3,4-thiadiazole; breast cancer; cytotoxic activity; docking studies.

MeSH terms

  • Cell Line, Tumor
  • Cell Proliferation
  • Humans
  • MCF-7 Cells
  • Thiadiazoles* / pharmacology

Substances

  • Thiadiazoles
  • 1,3,4-thiadiazole